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Abstract 
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status that regulates 
cellular and whole body energy balance. A recent crystal structure has illuminated the complex 
regulatory mechanisms by which AMP and ADP cause activation of AMPK, involving 
phosphorylation by the upstream kinase, LKB1. Once activated by falling cellular energy status, 
AMPK activates catabolic pathways that generate ATP, while inhibiting anabolic pathways and 
other cellular processes consuming ATP. 
 AMPK is implicated in many human diseases. Mutations in the γ2 subunit cause heart disease 
due to excessive glycogen storage in cardiac myocytes, leading to ventricular pre-excitation. 
AMPK-activating drugs reverse many of the metabolic defects associated with insulin resistance, 
and recent studies suggest that the insulin-sensitizing effects of the widely used anti-diabetic drug, 
metformin, are mediated by AMPK. The upstream kinase LKB1 is a tumor suppressor, and AMPK 
may exert many of its anti-tumor effects. AMPK activation promotes the oxidative metabolism 
typical of quiescent cells, rather than the aerobic glycolysis observed in tumor cells and cells 
involved in inflammation, explaining in part why AMPK activators have both anti-tumor and anti-
inflammatory effects. Salicylate (the major in vivo metabolite of aspirin) activates AMPK, and this 
could be responsible for at least some of the anti-cancer and anti-inflammatory effects of aspirin. In 
addition to metformin and salicylates, novel drugs that modulate AMPK are likely to enter clinical 
trials soon. Finally, AMPK is implicated in viral infection: down-regulation of AMPK during 
hepatitis C virus infection appears to be essential for efficient viral replication. 
 
KEYWORDS: metformin; cancer; type 2 diabetes mellitus; Wolff-Parkinson-White syndrome; cell 
biology; biochemistry 
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Introduction 
The AMP-activated protein kinase (AMPK) was originally discovered as apparently distinct protein 
kinase activities that phosphorylated and inactivated two key enzymes of lipid biosynthesis, i.e. 
acetyl-CoA carboxylase, involved in fatty acid synthesis [1], and 3-hydroxy-3-methylglutaryl-CoA 
reductase, involved in sterol synthesis [2]. In 1987 the author’s laboratory reported that these were 
functions of a single protein kinase that was activated allosterically by AMP, as well as by 
phosphorylation by a distinct upstream kinase [3]; we named it the AMP-activated protein kinase 
(AMPK) at that time [4]. 
 Since these early studies it has become clear that AMPK has dozens of physiological targets, and 
is a crucial regulator of energy balance, both at the cellular and at the whole body levels. Given the 
crucial nature of energy balance in the function of cells and organisms, it is not surprising that the 
AMPK system has many implications in human health, with roles in diverse disorders such as heart 
disease, diabetes, cancer, inflammatory disorders and viral infection. Some drugs that are already 
widely used, including metformin and salicylates, now appear to act in part by activating AMPK, 
while several novel AMPK-activating drugs are under development. The purpose of this review is 
to discuss the implications of recent discoveries about the AMPK system in the development and 
treatment of human disease. 
AMPK –regulation by adenine nucleotides and calcium ions 
AMPK appears to exist throughout eukaryotes as heterotrimeric complexes composed of a catalytic 
α subunit and regulatory β and γ subunits [5] (Fig. 1, top). Each subunit occurs in mammals as 
multiple isoforms (α1, α2; β1, β2; γ1, γ2, γ3) encoded by distinct genes. The site that upstream 
kinases phosphorylate to cause AMPK activation was identified within the rat α2 isoform as 
Thr172 [6]. Phosphorylation of this site, and the critical site on the downstream target acetyl-CoA 
carboxylase (Ser79 in rat ACC1 [7]), both usually monitored using phosphospecific antibodies, are 
now widely used as biomarkers for AMPK activation. 
 What is the physiological significance of activation of AMPK by AMP? The major source of 
AMP in the cell is the reaction catalyzed by adenylate kinase (2ADP ↔ ATP + AMP), which 
appears to be maintained close to equilibrium in most eukaryotic cells. In unstressed cells, 
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catabolism maintains the ATP:ADP ratio at around 10:1, and this drives the adenylate kinase 
reaction towards ADP, so that AMP is maintained at low levels. However, if the cells experience a 
metabolic stress that causes the ATP:ADP ratio to fall, the adenylate kinase reaction will tend to be 
displaced towards AMP. Because it starts at such a low level, the changes in AMP concentration in 
stressed cells are always much larger than the changes in ATP or ADP [8]. Cellular AMP 
concentrations are thus sensitive indicators of energy stress. 
 The principal upstream kinase phosphorylating Thr172 was identified in 2003 to be a complex 
containing the protein kinase LKB1 [9-11]. This was an exciting discovery because LKB1 had 
previously been identified as the product of a tumor suppressor gene mutated in an inherited 
susceptibility to cancer, Peutz-Jeghers syndrome [12], although its downstream targets had not been 
identified. These findings introduced the first clear link between AMPK and cancer, which is 
discussed further below. 
 Binding of AMP to AMPK causes >10-fold allosteric activation, and also promotes net 
phosphorylation of Thr172, both by stimulating phosphorylation by LKB1, and by inhibiting 
dephosphorylation by protein phosphatases [8]. The latter effect of AMP, but not the other two, is 
mimicked by ADP [13], albeit only at 10-fold higher concentrations [8]. All three effects are 
antagonized by ATP, but concentrations of AMP observed in stressed cells cause allosteric 
activation and promote phosphorylation even in the presence of physiological concentrations of 
ATP [8]. 
 Thr172 can also be phosphorylated by the Ca2+/calmodulin-dependent kinase kinases, especially 
CaMKKβ [14-16], which represents an alternate upstream pathway by which AMPK can be 
activated by increases in intracellular Ca2+ in the absence of changes in AMP. There are conflicting 
findings concerning whether phosphorylation by CaMKKβ is promoted by AMP [8, 17], but since 
AMP binding inhibits Thr172 dephosphorylation, low concentrations of the two signals can act in 
an additive manner in any case [18]. Activation of AMPK by CaMKKβ is now known to occur in 
many physiological situations, including hippocampal neurons subject to depolarization [14], T 
cells activated by antigen [19], and cells treated with agonists that activate G protein-coupled 
receptors linked (via Gq/G11) to release of intracellular inositol trisphosphate (IP3) and hence Ca2+. 
The latter include thrombin acting via protease-activated receptor-1 (PAR-1) in endothelial cells 
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[20], and ghrelin acting via growth hormone secretagogue receptor-1 (GHSR1) in hypothalamic 
neurons [21]. 
 To conclude this section, binding of AMP to AMPK promotes its activation by three 
complementary mechanisms: (i) allosteric activation; (ii) promoting phosphorylation of Thr172 by 
LKB1; (iii) inhibiting dephosphorylation of Thr172 by protein phosphatases, with only the third of 
these being mimicked by ADP. Phosphorylation of Thr172 can also occur in response to an increase 
in intracellular Ca2+. In the next section, I will discuss how structural studies on AMPK have 
illuminated this complex regulatory mechanism. 
Structure of the AMPK complex 
A crystal structure of a complete human α2β1γ1 complex was recently reported [22]. The complex 
had been phosphorylated at Thr172 and crystallized in the presence both of the classical allosteric 
activator AMP and a novel pharmacological activator called “991”, and was therefore in a fully 
active conformation, although the non-specific kinase inhibitor staurosporine was also included 
during crystallization. The layout of all of the major globular domains was clear, although some 
linking peptides were not fully resolved (Fig. 1).  
 The catalytic kinase domain (α-KD) is located at the N-terminal end of the α subunit and has the 
archetypal kinase domain structure, with small and large lobes joined by a hinge. As expected, the 
inhibitor staurosporine was located in the cleft between these lobes, where it occupies the site used 
by ATP during catalysis. Although a peptide substrate was not present in this structure, previous 
biochemical studies had suggested that the peptide sequence N-terminal to the phosphorylated 
residue on a substrate binds in a groove in the surface of the large lobe, placing the 
phosphoacceptor adjacent to the γ-phosphate of bound ATP [23]. The α-KD is immediately 
followed by a small auto-inhibitory domain (α-AID), so-called because α-KD:α-AID constructs are 
much less active than those containing the α-KD alone [24]; reorientation of the position of the α-
AID relative to the α-KD is likely to be involved in the activation mechanism [22]. The C-terminal 
end of the α-AID marks the boundary between what can be termed the “catalytic module” (top left 
in the lower part of Fig. 1) and the rather discrete “nucleotide-binding module” (bottom right in Fig. 
1), with the later containing the C-terminal domains of the α and β subunits (α- and β-CTD) as well 
as the entire γ subunit. The critical phosphorylation site, Thr172, lies in the cleft between these two 
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modules, and in the active conformation shown in Fig. 1 access of protein phosphatases to Thr172 
would be restricted by the close proximity of the α-CTD. 
 The β subunits contain two conserved globular domains, the carbohydrate-binding module (β-
CBM) and the previously mentioned β-CTD. The β-CTD acts as the core of the heterotrimeric αβγ 
complex, bridging the α-CTD to the γ subunit. Although the connections between the β-CBM and 
the β-CTD are not fully resolved, the former lies on the opposite side of the kinase domain to the 
latter, with 991 and A-769662 binding in the cleft between the β-CBM and the small lobe of the 
kinase domain. These two compounds are synthetic ligands derived from high-throughput screens 
designed to detect AMPK activators, and their binding causes both allosteric activation and 
inhibition of Thr172 dephosphorylation. The effects of their binding may be transmitted to the 
kinase domain via the “C-interacting helix” on the β subunit, which immediately follows the β-
CBM and which interacts with the C-helix on the small lobe of the kinase domain. On the opposite 
side of the β-CBM from the 991-binding site is the glycogen-binding site. Although this is known 
to be responsible for binding of AMPK to the surface of glycogen particles [25, 26], its exact 
physiological role remains uncertain. 
 The γ subunits contain an N-terminal region involved in interaction with the β-CTD, and then 
four tandem repeats (CBS1-CBS4) of a sequence motif known as a cystathione β-synthase (CBS) 
repeat, each represented in a different color in Fig. 1. CBS repeats occur, usually as just two tandem 
repeats, in other human proteins where they often bind ligands containing adenosine [27]. 
Intriguingly, mutations in conserved residues within CBS repeats disrupt ligand binding, and 
several of these (including those in the AMPK-γ2 subunit, see below) cause inherited diseases in 
humans [27]. The four CBS repeats in the AMPK-γ subunits assemble in a pseudosymmetrical 
manner to generate a flattened disk, with four clefts in the centre where ligands might bind. 
However, only three of these appear to be utilized, and these represent the sites where the 
regulatory ligands, AMP, ADP and ATP bind in competition with each other. Interestingly, the α-
AID and the α-CTD are connected by an extended linker peptide, which in the active conformation 
in Fig. 1 wraps around one face of the γ subunit, forming a structure called the “α hook” that 
contacts AMP in site 3. A previously proposed model [13] suggests that binding of AMP or ADP, 
but not ATP, in site 3 would allow interaction with the α hook. The consequent conformational 
change in the α-linker peptide when ATP binds was proposed to cause the nucleotide-binding and 
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catalytic modules to move apart, allowing protein phosphatases better access to Thr-172 and thus 
explaining the ability of AMP and ADP binding to inhibit Thr172 dephosphorylation. 
Downstream effects of AMPK activation 
A full discussion of the known downstream targets for AMPK is beyond the scope of this review, 
and readers are referred to a previous review [5]. However, a summary of some of these, and the 
pathways they regulate, is shown in Figure 2. Consistent with the findings that it is switched on by 
ATP depletion, and has a key role in maintaining cellular energy balance, AMPK promotes 
catabolic pathways that generate ATP, while inhibiting anabolic pathways involved in cell growth, 
and other processes that consume ATP. It also causes a cell cycle arrest in G1 phase [28], in part by 
phosphorylating MDM4 (MDMX), part of the E3 ubiquitin ligase complex that regulates p53 
turnover [29]. Cell cycle arrest by AMPK makes sense, since DNA replication (during S phase) and 
mitosis (M phase) are both energy-requiring processes. In general, AMPK achieves its effects both 
acutely via direct phosphorylation of metabolic enzymes or regulatory proteins involved in the 
process being regulated, and in the longer term via effects on gene expression. I will discuss here 
just a few examples of downstream effects of AMPK that will become relevant later in the review: 
1) AMPK accelerates glucose uptake to drive catabolism of glucose during muscle contraction, 
which it does, at least in part, by phosphorylating the Rab-GTPase activator protein (Rab-GAP), 
TBC1D1 (Fig. 3). TBC1D1 is a member of the same family as TBC1D4 (also known as AS160), 
whose phosphorylation by the insulin-activated kinase PKB/Akt plays a key role in insulin-
stimulated glucose uptake [30]. While TBC1D4 appears to be the predominant form in 
adipocytes, TBC1D1 is the predominant form in most muscle types [31]. Both TBC1D1 and 
TBC1D4 bind to intracellular vesicles containing the glucose transporter GLUT4, and their Rab-
GAP domains promote the GTPase activity of members of the Rab family of small G proteins, 
thus maintaining them in their inactive, GDP-bound state. Phosphorylation of TBC1D1 at two 
sites, Ser237 and Thr596, promotes its binding to 14-3-3 proteins, which appears to repress its 
Rab-GAP activity. Rabs are thus converted to their active GTP-bound forms, and they then 
promote trafficking of the GLUT4-containing intracellular vesicles to the plasma membrane and 
thus increased glucose uptake [32-34]. While AMPK can phosphorylate both Ser237 and Thr596 
in cell-free assays, available evidence suggests that only Ser237 may be phosphorylated by 
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AMPK in intact cells, with Thr596 being phosphorylated by other kinases including the insulin-
stimulated kinase, Akt [32]. 
2) AMPK phosphorylates and inactivates both isoforms of acetyl-CoA carboxylase, ACC1 and 
ACC2, lowering the concentration of their reaction product, malonyl-CoA. Since malonyl-CoA 
is both an intermediate in fatty acid synthesis and an inhibitor of fatty acid uptake into 
mitochondria via the transport system involving carnitine:palmitoyl transferase-1 (CPT1), this 
has the dual effect of inhibiting fatty acid synthesis and enhancing fatty acid oxidation (Fig. 4) 
[35, 36]. 
3) AMPK enhances mitochondrial biogenesis by effects on the transcriptional co-activator PGC-
1α. This may involve direct phosphorylation of PGC-1α [37], or activation of the lysine 
deacetylase SIRT1, which deacetylates and activates PGC-1α [38]. 
4) As well as its direct effects on acetyl-CoA carboxylase, AMPK inhibits fatty acid synthesis in 
the longer term by phosphorylating SREBP-1c, inhibiting its ability to promote transcription of 
lipogenic enzymes [39]. AMPK also inhibits cholesterol and phospholipid/triacylglycerol 
synthesis, the former by phosphorylating and inactivating HMG-CoA reductase (HMGR) [35], 
and the latter by inactivating glycerol phosphate acyl transferase (GPAT; it remains unclear 
whether this is via direct phosphorylation) [40]. 
5) AMPK inhibits two other major biosynthetic pathways required for cell growth, i.e. protein and 
rRNA synthesis. It inhibits the former mainly by inhibiting the mechanistic target-of-rapamycin 
complex-1 (mTORC1), by phosphorylating both the upstream regulator TSC2 [41] and the 
mTORC1 subunit, Raptor [42] (Fig. 5). AMPK also inhibits rRNA synthesis by phosphorylating 
TIF-1A, a transcription factor for RNA polymerase-1 [43]. 
Role of AMPK in hypertrophic cardiomyopathy 
The only disease-causing mutations currently identified in AMPK genes are in PRKAG2 (encoding 
the γ2 isoform of the nucleotide-binding subunit), which cause a form of the heart disease Wolff-
Parkinson-White syndrome [44]. This syndrome is characterized by ventricular pre-excitation (a 
premature excitation of the ventricles, readily detected by electrocardiogram), but when caused by 
PRKAG2 mutations it is usually, although not always [45], accompanied by cardiac hypertrophy. 
More than ten different mutations in PRKAG2 have been identified, all of which cause amino acid 
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substitutions within the CBS repeats of γ2 [44]. Most are inherited in a dominant manner and are 
thus frequent in the affected families, although some (e.g. R384T in CBS2 [46] and R531Q in 
CBS4 [47]) cause a more severe form of disease associated with death during infancy, and are 
therefore only found as de novo mutations not present in the parents. Many of the substitutions 
(R302Q, H383R, R384T, R531G, R531Q) affect basic side chains that occur at similar positions in 
CBS repeats 1, 2 and 4, and structural studies show that these positively charged side chains bind 
the negatively charged phosphate groups of the bound adenine nucleotides [48]. These substitutions 
not only reduce allosteric activation, but also the enhanced net Thr172 phosphorylation caused by 
AMP binding [27, 46, 47, 49]. Other substitutions (e.g. T400N and N488I), although not appearing 
to affect residues directly involved in nucleotide binding, still negatively affect AMP binding. 
Reduced AMP activation is clearly a loss-of-function effect, which is difficult to reconcile with 
dominant inheritance of the mutations. However, since the mutations affect binding of the 
inhibitory nucleotide, ATP, as well as the activating nucleotide, AMP [27], the most likely 
explanation is that they reduce binding of ATP and thus increase basal Thr172 phosphorylation and 
AMPK activity, a gain-of-function effect. This has been directly demonstrated with the R531G and 
R531Q substitutions [47, 50], while the effects of mutations equivalent to T400N and N488I made 
in the γ subunit ortholog in budding yeast also suggest a gain-of-function [51]. In addition, elevated 
basal AMPK activity was observed in transgenic mice over-expressing the N488I mutation in the 
heart [52]. 
 One feature of the cardiac myocytes of these patients, based on post mortem analysis, is the 
presence of large vacuole-like structures containing glycogen, which appear to disrupt the normal 
myofibrillar structure [51]. The hearts of children bearing the R531Q and R384T mutations 
displayed gross hypertrophy and also contained up to 10 times the normal glycogen content [46, 
47]. Transgenic mice over-expressing γ2 from a cardiac-specific promoter with R302Q [53], N488I 
[52] or R531G [54] mutations, but not wild type γ2, also displayed gross cardiac hypertrophy, 
ventricular pre-excitation and elevated cardiac glycogen. Thus, the γ2 mutations appear to cause a 
glycogen storage disorder, but why should this lead to ventricular pre-excitation? The atria and 
ventricles of normal adult hearts are separated by a fibrous ring containing collagen (the annulus 
fibrosis), which ensure that electrical excitation passes from the atria to the ventricles only through 
the atrio-ventricular node (where a short delay is imposed), and cannot then return to the atria. 
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Without a fully intact annulus fibrosis, ventricular pre-excitation and potentially fatal arrhythmias 
can occur. Studies of transgenic mice over-expressing the N488I mutation showed that the fibrous 
rings were disrupted by glycogen-filled myocytes [52], which may account for the ventricular pre-
excitation exhibited by these mice. 
 The elevated glycogen content can therefore potentially explain the cardiac arrhythmias, but why 
do the mutations cause high glycogen? The most likely explanation is that the elevated basal 
Thr172 phosphorylation and AMPK activity enhances GLUT4 translocation and glucose uptake. 
Evidence in favor of this idea comes from studies of the transgenic mice over-expressing the N488I 
mutation [55], which have elevated cardiac glucose uptake, glycogen synthesis and glucose-6-
phosphate content (the latter a key allosteric activator of glycogen synthase), as well as increased 
ACC phosphorylation and fatty acid oxidation. Interestingly, when the N488I over-expressing mice 
were crossed with mice carrying a point mutation in the GYS1 gene that rendered its product, 
glycogen synthase, resistant to glucose-6-phosphate activation, both the glycogen storage and the 
ventricular pre-excitation were almost completely reversed [56]. These results suggest that the 
increased basal AMPK activity causes enhanced glucose uptake into cardiac myocytes but that, in 
the absence of a genuine increased demand for glucose, glucose-6-phosphate concentrations rise 
thus driving flux of glucose carbon into glycogen synthesis rather than glycolysis and oxidation. 
The cells are, in effect, behaving as if they were short of energy even though they are not. Tellingly, 
however, although the glycogen storage and ventricular pre-excitation phenotypes of the N488I 
mice were reversed by crossing with the GYS1 mutants, their cardiac hypertrophy was not, showing 
that the latter has a distinct origin. The authors suggested that this was due to enhanced insulin 
sensitivity of the cardiac myocytes, leading to hyper-activation of the mTORC1 pathway. 
Consistent with this, the hypertrophy could be largely reversed by treatment with the mTORC1 
inhibitor, rapamycin [56]. 
 The γ2 isoform is expressed most abundantly in the heart, although also expressed elsewhere 
[57]. Similar mutations have not been reported to occur in the γ1 isoform, but they have been found 
in γ3, which is expressed almost exclusively in skeletal muscle [57]. An R200Q substitution in γ3 in 
domestic pigs (equivalent to the R302Q substitution in human γ2) is associated with a high 
glycogen content in skeletal muscle, which adversely affects meat quality [58]. Intriguingly, in a 
screen of candidate genes in 1500 lean and obese humans, a heterozygous mutation causing an 
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R225W substitution in γ3 (R225 aligns with R302 in human γ2 and R200 in pig γ3) was found in 
two unrelated individuals. In these subjects, skeletal muscle glycogen content and basal AMPK 
activity were 2-fold higher, while intramuscular triglyceride was 30% lower than in matched 
controls. In both the pigs and the humans, there was no obvious clinical problem associated with the 
γ3 mutation, and it is interesting to speculate that some endurance athletes might carry γ3 mutations, 
because a high muscle glycogen content would be expected to confer an advantage in endurance 
events. Relevant to this, it is interesting to note that the AMPK activator 5-aminoimidazole-4-
carboxamide riboside (AICAR), which increases muscle glycogen content [59] and improves 
endurance on treadmills when administered to sedentary mice over several weeks [60], has been 
banned for use in sport by the World Anti-Doping Agency. 
Role of AMPK in type 2 diabetes 
Type 2 diabetes occurs when increased release of insulin from the β cells of the pancreas can no 
longer compensate for insulin resistance, with the latter being strongly associated with increased 
triacylglycerol content, particularly in liver and skeletal muscle. One hypothesis is that insulin 
resistance occurs in obese individuals when their capacity to store triacylglycerols in adipose tissue 
is exceeded, leading to their accumulation in liver and muscle. This is supported by studies of 
humans with lipodystrophy, who lack adipose tissue and store triacylglycerols instead in liver and 
muscle, which then become severely insulin resistant [61]. Despite the association between insulin 
resistance and triacylglycerols, the real culprit may be diacylglycerols whose levels are elevated at 
the same time. Diacylglycerols activate novel isoforms of protein kinase C (PKCθ in muscle and 
PKCε in liver) that then appear to down-regulate the insulin signaling pathway [61]. This represents 
one explanation of the insulin resistance associated with obesity, although other factors such as 
increased inflammation [62] or endoplasmic reticulum stress [63] may also play a part. However, 
AMPK activation may be able to reverse both of these as well, since it has anti-inflammatory 
effects (discussed below) while inhibition of protein synthesis by AMPK has the potential to relieve 
endoplasmic reticulum stress. 
 By promoting the oxidation of fatty acids and inhibiting synthesis of fatty acids and 
triacylglycerols, treatments that activate AMPK would be expected to reduce lipid stores in liver 
and skeletal muscle and hence improve insulin sensitivity. By promoting glucose uptake by skeletal 
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muscle [36, 64] and inhibiting gluconeogenesis in the liver [65, 66], they might also be expected to 
ameliorate the hyperglycemia associated with type 2 diabetes more directly. Indeed, 
pharmacological agents that activate AMPK do have many of these effects in vivo. The first to be 
tested was AICAR, an adenosine analogue that is taken up into cells via adenosine transporters and 
converted to the equivalent nucleotide, ZMP, which mimics all of the activating effects of AMP on 
AMPK [35]. AICAR treatment was found to reverse many metabolic abnormalities in animal 
models of obesity and insulin resistance, such as fa/fa rats [67, 68], ob/ob mice [69], and rats fed a 
high-fat diet [70]. At about the same time, it was reported that the biguanide drug metformin, 
currently the first choice drug for type 2 diabetes that is prescribed to >100 million patients 
worldwide, also activated AMPK both in intact cells and in vivo [71]. Metformin activates AMPK 
indirectly by inhibiting the mitochondrial respiratory chain [50], but A-769662, a direct AMPK 
activator that binds at the same site as 991 (Fig. 1), also has similar in vivo effects in animals; it 
increases fatty acid oxidation in rats, and decreases plasma glucose, body weight gain, plasma and 
liver triacylglycerols, and hepatic expression of gluconeogenic and lipogenic enzymes in ob/ob 
mice [72]. Similarly, the natural product berberine used in traditional Chinese medicine, which 
activates AMPK by inhibiting the respiratory chain in a similar manner to metformin [50], also 
reduces body weight and improves glucose tolerance in db/db mice, while reducing body weight 
and plasma triacylglycerols, and improving insulin sensitivity, in rats fed a high-fat diet [73]. 
 Since (with the exception of A-769662) these agents activate AMPK indirectly, it has been 
important to establish whether their favorable metabolic effects are indeed mediated by AMPK. 
Arguing against this, the ability of AICAR or metformin to reduce glucose production by 
hepatocytes in vitro, or of metformin to improve glucose tolerance after short-term (30 minute) 
treatment in vivo, was unaffected by a knockout of both isoforms of the AMPK catalytic subunit 
(α1 and α2) in the liver [74]. The AMPK-independent effects of AICAR may be due to effects of 
its intracellular metabolite, ZMP, to directly inhibit the gluconeogenic enzyme fructose-1,6-
bisphosphatase [75] and/or to lower cyclic AMP (which promotes transcription of gluconeogenic 
enzymes) due to inhibition of adenylate cyclase [76], while the AMPK-independent effects of 
metformin in part may a consequence of ATP depletion, which was more severe in cells lacking 
AMPK [74]. Despite these negative findings, there is good evidence that the longer term insulin-
sensitizing effects of metformin are mediated by AMPK. This comes from recent studies of “double 
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knock-in” (DKI mice) in which both endogenous genes encoding acetyl-CoA carboxylase (ACC1 
and ACC2) were replaced by genes encoding single amino acid substitutions that eliminate the 
AMPK sites [77]. As expected, the ACC1/ACC2 activities, and the cellular content of the product 
malonyl-CoA, were elevated in the livers of these mice, and fatty acid oxidation was reduced. This 
was in turn associated with increased levels of hepatic di- and tri-acylglycerols and increased PKCε 
activity, while the mice had increased fasting blood glucose and insulin, were glucose-intolerant 
and insulin-resistant, and insulin was less effective at suppressing hepatic glucose production. Even 
more interesting was the effect of feeding a high-fat diet, which obliterated the metabolic 
differences between the wild type and DKI mice. However, while long-term (6 week) treatment 
with metformin improved metabolic parameters such as fasting blood glucose, insulin suppression 
of hepatic glucose production and gluconeogenic enzyme expression in the fat-fed wild type 
animals, all of these effects were absent in the DKI mice. These results suggest that the insulin-
sensitizing effects of metformin can be almost entirely attributed to its effects on fatty acid 
metabolism, mediated by AMPK. 
Role of AMPK in cancer 
The first link between AMPK and cancer came with the finding that LKB1 is the upstream kinase 
required for AMPK activation in response to energy stress and biguanide drugs [9-11]. Mutations in 
the gene encoding LKB1 were already known to cause Peutz-Jeghers syndrome in humans. Humans 
with this syndrome are heterozygous for mutations that cause a loss of kinase activity, and they 
develop frequent benign intestinal tumors (polyps) that in mouse models appears to be due to 
haploinsufficiency [78]. They also have an increased risk of developing malignant cancers at other 
sites, which in mice appears to be due to loss-of-heterozygosity in somatic cells [79]. LKB1 is 
therefore a classical tumor suppressor, raising the question as to whether its tumor suppressing 
effects are mediated by AMPK. LKB1 is also required for phosphorylation and activation of a 
family of twelve “AMPK-related kinases” that have kinase domains closely related to AMPK [80]. 
While one or more of these might also contribute to the tumor suppressor effects of LKB1, AMPK 
remains the best candidate because of its ability to inhibit mTORC1 and almost all biosynthetic 
pathways required for cell growth, and to cause cell cycle arrest. In addition, tumor cells and other 
rapidly proliferating cells tend to have greatly elevated rates of glucose uptake and glycolytic 
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metabolism (termed the Warburg effect or aerobic glycolysis), this metabolic switch being required 
in part to provide precursors for biosynthesis [81]. In the longer-term, AMPK activation tends to 
promote the more energy-efficient oxidative metabolism utilized by quiescent cells, thus opposing 
the switch to the aerobic glycolysis observed in many tumor cells. 
 Consistent with the idea that AMPK is a tumor suppressor are results showing that the AMPK 
activators metformin, phenformin and A-769662 all delay tumor onset in tumor-prone mice [82], 
and that a whole body knock-out of AMPK-α1 (the only catalytic subunit expressed in 
lymphocytes) accelerates the development of lymphomas in transgenic mice over-expressing the 
Myc oncogene in B cells [83]. In the latter case, this was accompanied by a shift towards aerobic 
glycolysis, which (as argued above) might be opposed if AMPK was present. This shift was 
dependent on hypoxia-inducible factor-1α, a transcription factor that up-regulates expression of 
glucose and lactate transporters and glycolytic enzymes [83]. Translation of HIF-1α mRNA is up-
regulated by mTORC1 [84], a signaling pathway that is switched off by AMPK (Fig. 5). 
 The original finding that the tumor suppressor LKB1 lay on the same pathway as AMPK 
inspired epidemiological studies showing that diabetics treated with metformin had a lower 
incidence of cancer than those on other medications [85], a finding reproduced in many subsequent 
studies [86]. There are several possible explanations for this association, and it is not yet certain that 
the effect is mediated by AMPK, nor that it is an effect of metformin on the tumor cells themselves. 
There is some evidence from a mouse xenograft model that it may be mediated in part by 
metformin acting on the liver, lowering plasma glucose and insulin, with the latter being thought to 
trigger increased tumorigenesis in insulin-resistant states [87]. There is also evidence from mouse 
models that metformin and the related biguanide phenformin prolong survival by triggering more 
apoptosis in tumor cells that have lost LKB1, because the lack of a functional AMPK pathway in 
such cells makes them more sensitive to ATP depletion caused by the biguanide [87, 88]. If this 
mechanism operates in humans, then biguanides might be most effective in treating cancers where 
the LKB1-AMPK has been lost, which is quite a frequent occurrence (see next paragraph). It might 
also make sense for phenformin rather than metformin to be used for cancer treatment, because 
being more hydrophobic and less dependent on OCT1 for cellular uptake [50], it can probably enter 
tumor cells more readily. 
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 If the LKB1-AMPK axis is indeed a tumor suppressing pathway that restrains tumor growth, you 
would expect tumor cells to be under selection pressure to down-regulate it. Consistent with this, 
biallelic loss-of-function mutations in LKB1 are common in human cancers, occurring in up to 30% 
of non-small cell lung cancers [89, 90], 20% of cervical cancers [91], and 10% of melanomas [92]. 
Loss of LKB1 leads to failure of AMPK activation during energy stress [9]. Mutations in the 
subunits of AMPK itself seem to be much less common in human cancer, possibly because (unlike 
LKB1) each subunit is encoded by more than one gene. However, down-regulation of expression of 
AMPK-α2 is relatively frequent in hepatocellular carcinoma, and is associated with poor prognosis 
[93]. Finally, the growth-promoting protein kinase B/Akt pathway is hyper-activated in many 
human cancers, either by activating mutations in phosphatidylinositide 3-kinase (PI3K) or receptors 
upstream of it, or loss-of-function mutations in PTEN, which is the tumor suppressor that degrades 
PIP3, the PI3K product and second messenger for protein kinase B (also known as Akt) [94]. It was 
shown in 2006 [95] that PKB/Akt phosphorylates Ser485 on rat AMPK-α1, and that this inhibited 
subsequent phosphorylation of the activating site, Thr172, by LKB1. The author’s group has 
recently confirmed that Akt phosphorylates the equivalent site (Ser487) on human AMPK-α1 
(although not the equivalent site on AMPK-α2, Ser491, which is modified instead by 
autophosphorylation) [96]. These sites lie within a loop of about 50 residues that the author terms 
the “ST loop” due to its serine/threonine-rich nature. In the structure shown in Fig. 1 this loop was 
not resolved, but it would loop out of the rear side of the α-CTD (shown with a dashed line in Fig. 
1). Because the complex may not be phosphorylated on the ST loop after expression in bacteria it is 
likely to be mobile within the crystals, but we have provided evidence that, after phosphorylation on 
Ser487 and possibly other sites, the ST loop interacts with the C-helix on the kinase domain, thus 
blocking access of upstream kinases to Thr172 [96]. We also showed that Ser487 was 
phosphorylated in three different human tumor cell lines where Akt was hyperactivated due to loss 
of PTEN. In these cells, AMPK was rather resistant to Thr172 phosphorylation and activation, but 
this could be rescued either by addition of an Akt inhibitor or by re-expressing PTEN, both of 
which triggered net dephosphorylation of Ser487 [96]. These results show that a previously 
unrecognized effect of Akt hyper-activation in tumor cells is that it down-regulates the AMPK 
pathway, thus reducing its restraining influence on cell growth and division. Since Ser487 
phosphorylation inhibits but does not totally block Thr172 phosphorylation, they also suggest that 
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this down-regulation might be overcome using AMPK-activating drugs, indicating a potential 
therapeutic role for the latter in tumors where the Akt pathway is hyper-activated. 
Role of AMPK in inflammatory disease 
There is increasing evidence that AMPK has anti-inflammatory effects, and that this may be 
mediated by its metabolic actions [97]. Unactivated cells of the immune system, including dendritic 
cells, neutrophils and T cells, utilize mainly oxidative metabolism (including fatty acid oxidation) to 
generate ATP. However, once activated, they usually switch to aerobic glycolysis, analogous to the 
metabolic changes that occur in tumor cells. In dendritic cells this switch is associated with reduced 
AMPK activation, is inhibited by pharmacological activation of AMPK, and is promoted by AMPK 
down-regulation [98].  Similar effects are observed in macrophages: classically activated (M1) 
macrophages with a pro-inflammatory role utilize aerobic glycolysis, whereas alternatively 
activated (M2) macrophages, more involved in the resolution of inflammation, tend to utilize 
oxidative metabolism instead. Studies using macrophages where AMPK has been down-regulated 
suggest that AMPK normally attenuates production of inflammatory cytokines [99, 100].  The idea 
that the anti-inflammatory actions of AMPK are due to its metabolic actions was strengthened by 
studies with mouse knockouts of AMPK-β1, the predominant β subunit isoform expressed in 
macrophages. AMPK-β1 deficient macrophages displayed reduced ACC phosphorylation and 
mitochondrial content, and reduced rates of fatty acid oxidation that promoted the accumulation of 
pro-inflammatory diacylglycerols. This triggered M1 skewing in vivo in macrophages derived from 
both bone marrow and adipose tissue. Activation of AMPK with A-769662 increased fatty acid 
oxidation in wild type but not β1-deficient macrophages, and the effects of A-769662 to suppress 
inflammation were impaired if fatty acid oxidation was blocked [101]. These findings suggest that a 
major component of the anti-inflammatory action of AMPK is mediated via its effects on fatty acid 
oxidation. The role of AMPK in macrophages has also been studied using mice with global or 
myeloid-specific knockouts of AMPK-α1, the catalytic subunit isoform expressed in macrophages. 
Regeneration of muscle in response to muscle injury was defective in these mice, and this was 
associated with reduced skewing towards M2 macrophages [102]. 
 Interestingly, the author’s laboratory has shown that AMPK is directly activated by salicylate, 
the natural product from which aspirin (acetyl salicylate) was derived [103]. Salicylate and A-
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769662 appear to bind to the same site on AMPK; both are selective activators of β1-containing 
complexes, and they increase whole body fatty acid oxidation in wild type but not β1 knockout 
mice, showing that increased fat oxidation is mediated by AMPK activation in vivo. Although 
AMPK is not directly activated by aspirin itself [103], aspirin is rapidly broken down to salicylate. 
Indeed, following oral administration of aspirin the plasma half-life and peak concentration of its 
breakdown product, salicylate, are orders of magnitude greater than those of aspirin itself. Although 
blockade of prostanoid biosynthesis, via inhibition of cyclo-oxygenases, has been considered to be 
the main mechanism of action of aspirin, there has always been a paradox in that, while aspirin and 
salicylate have similar anti-inflammatory potencies, salicylate is a very poor inhibitor of cyclo-
oxygenase [104, 105]. Although significant AMPK activation requires at least 1 mM salicylate, 
such concentrations are reached in humans taking high doses of aspirin or another salicylate 
derivative, salsalate, for rheumatoid arthritis. This raises the intriguing possibility that at least some 
of the anti-inflammatory effects of salicylate-based drugs may be mediated by AMPK. Intriguingly, 
the regular use of aspirin is also associated with reduced incidence of cancer [106], although 
whether this effect is mediated by AMPK remains uncertain. 
Role of AMPK in viral infection 
Hepatitis C virus is a positive-sense, single-stranded RNA virus with a lipid envelope, and it is 
estimated that an infected hepatocyte produces up to 50 viral particles per day. Because this 
requires synthesis of viral protein and lipids as well as RNA, one might imagine that it would cause 
increased ATP turnover and hence AMPK activation, which might then restrain further viral 
replication. Paradoxically, however, AMPK activation is down-regulated in a cell culture model of 
hepatitis C virus infection [107]. This appears to be because the viral protein NS5A binds to and 
activates PI3K, thus switching on the PKB/Akt pathway [108]. PKB/Akt would promote protein 
and lipid synthesis and cell survival, but would also down-regulate AMPK via phosphorylation 
AMPK-α1 at Ser487 within the ST loop (see section on cancer above). Indeed, experiments 
involving transfection of an S487A mutant suggested that phosphorylation of Ser487 is required for 
efficient viral replication [107]. Although the role of AMPK in viral infection is a relatively new 
area, there are indications that other viruses also interact with the AMPK system [109]. 
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The potential application of novel AMPK-modulating drugs 
An important consideration in the development of novel AMPK activating drugs is that they would 
have to be significantly more effective than existing agents such as metformin or salicylates, which 
are both inexpensive and have a good safety record. One potential shortcoming with metformin is 
that its effects appear to be largely confined to the liver. Since it is a cation that is not readily cell-
permeable, the uptake of metformin into cells requires membrane transporters of the organic cation 
transporter family, such as OCT1 [110]. Because hepatocytes are exposed to higher concentrations 
of orally delivered metformin via the portal vein than most other cells [71], and also express high 
levels of OCT1, effects of metformin in vivo may be largely restricted to the liver [110]. In 
particular, the drug may not cause much activation of AMPK in skeletal muscle because of low 
peripheral drug concentrations and low OCT1 expression. The doses of metformin that can be 
administered to humans are limited by gastrointestinal side effects, which are likely to be AMPK-
independent and may be caused by inhibition of the respiratory chain and consequent lactate 
production in the liver or gut [111, 112]. The more hydrophobic biguanide phenformin is more cell-
permeable than metformin, and therefore much less dependent on OCT1 for cellular uptake [50]. 
Although formerly used for treatment of Type 2 diabetes, it was withdrawn in most countries in the 
1970s due to cases where persons taking the drug developed lactic acidosis (with hindsight, an 
unsurprising side effect since both biguanides inhibit the respiratory chain and that is how they 
activate AMPK [50]). However, the frequency of lactic acidosis with phenformin, while life-
threatening and around 20-fold more frequent than with metformin, was still rare (≈60 cases per 
100,000 patient-years) [112]. This small risk might be more acceptable if the drug was being used 
to treat cancer, rather than diabetes [88]. 
 The indirect AMPK activator AICAR, which is converted into the AMP mimetic ZMP within 
the cell [35], has the generic drug name acadesine and has been tested in humans [113]. However, it 
is not orally available and has to be injected and, as discussed above, has clear “off-target” AMPK-
independent effects in mice, so its potential as an AMPK-activating drug in humans seems limited. 
New direct AMPK activators that are readily cell-permeable, exemplified by 991 and A-769662 
[22], may have additional benefits over metformin by activating AMPK and promoting glucose 
uptake in organs other than the liver, especially skeletal muscle. These compounds are being 
developed by pharmaceutical companies, and studies of their potential toxicity are not yet available 
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within the public domain.  However, one caveat with their use is that increased glucose uptake into 
skeletal and cardiac muscle, in the absence of a demand for increased catabolism, would be 
expected to increase their glycogen content, as observed with the γ2 mutations that increase basal 
AMPK activity (see above). Nevertheless, while it is clear that increased glycogen content is 
harmful if it occurs during fetal development of the heart, it is not yet certain that it would be a 
problem in adults. Whether AMPK-activating drugs would also cause cardiac hypertrophy, which 
seems to be a secondary consequence of the activating γ2 mutations that is independent of their 
effects on glycogen accumulation [56], also remains unclear at present. However, adverse cardiac 
side effects would be a potential issue with any novel AMPK activators that would have to be 
carefully monitored, and the development of AMPK-activating drugs targeting isoform 
combinations not expressed in the heart, such as γ3 [57], might be advantageous. 
 Are there any indications for the development of inhibitors of AMPK? These might, of course, 
be useful for the treatment of the heart disease associated with γ2 mutations; studies using 
transgenic mice expressing the γ2 N488I mutation in the heart from a promoter switched off by 
tetracycline administration revealed that the clinical signs of the disease were at least partially 
reversible in mice [114]. A larger market for AMPK inhibitors might lie with treatment of those 
cancers where the LKB1-AMPK pathway, rather than being down-regulated as discussed above, 
has remained fully functional. There is evidence from mouse models that tumors with a functional 
LKB1-AMPK pathway are protected against cell death induced by addition of metformin or 
phenformin in vivo, compared with tumors lacking the pathway [87, 88]. In these cases, the 
biguanides may be acting as a kind of cytotoxic drug that acts by depleting cellular ATP, which is 
less harmful when AMPK is available to mount a response. It seems possible that the existence of a 
functional LKB1-AMPK pathway within tumor cells may also protect then against the effects of 
other cytotoxic drugs used for cancer treatment, in which case the latter might be usefully combined 
with an AMPK inhibitor. At present the only widely available AMPK inhibitor is compound C [71] 
(also known as dorsomorphin [115]), but that compound is in fact a rather non-selective kinase 
inhibitor [116], and much more specific inhibitors are needed. 
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Conclusions and perspectives 
It should be clear from the discussion above that AMPK plays an important role in several diseases 
that have a high prevalence within most human populations, including type 2 diabetes, cancer and 
inflammatory diseases. It also appears to be involved in one disorder (hepatitis C) that, while less 
common amongst the whole population, is nevertheless prevalent in certain subgroups. The fact that 
widely used drugs that have been in human use for fifty years (metformin) or even longer 
(salicylates) may work, at least in part, by activating AMPK suggests that AMPK activators are 
fertile ground for the development of novel drugs. There are many recent patents for such 
activators, and it seems likely that some of these may enter clinical trials soon. However, one caveat 
has emerged from the studies of mutations in AMPK-γ2 that cause excessive glycogen storage and 
ventricular pre-excitation in cardiac muscle. The adverse consequences of these mutations suggest 
that there could be some situations (e.g. in cardiac myocytes) where the activation of AMPK in the 
absence of real energy deficit may be undesirable. 
Acknowledgements 
Studies in the author’s laboratory are supported by Senior Investigator Award (097726) from the 
Wellcome Trust and by a Programm Grant (C37030/A15101) from Cancer Research UK. 
References 1	   Carlson	  CA,	  Kim	  KH.	  Regulation	  of	  hepatic	  acetyl	  coenzyme	  A	  carboxylase	  by	  phosphorylation	  and	  dephosphorylation.	  J	  Biol	  Chem	  1973;	  248:	  378-­‐80.	  2	   Beg	  ZH,	  Allmann	  DW,	  Gibson	  DM.	  Modulation	  of	  3-­‐hydroxy-­‐3-­‐methylglutaryl	  coenzyme:	  A	  reductase	  activity	  with	  cAMP	  and	  with	  protein	  fractions	  of	  rat	  liver	  cytosol.	  Biochem	  
Biophys	  Res	  Comm	  1973;	  54:	  1362-­‐9.	  3	   Carling	  D,	  Zammit	  VA,	  Hardie	  DG.	  A	  common	  bicyclic	  protein	  kinase	  cascade	  inactivates	  the	  regulatory	  enzymes	  of	  fatty	  acid	  and	  cholesterol	  biosynthesis.	  FEBS	  Lett	  1987;	  223:	  217-­‐22.	  4	   Hardie	  DG,	  Carling	  D,	  Sim	  ATR.	  The	  AMP-­‐activated	  protein	  kinase	  -­‐	  a	  multisubstrate	  regulator	  of	  lipid	  metabolism.	  Trends	  Biochem	  Sci	  1989;	  14:	  20-­‐3.	  5	   Hardie	  DG,	  Ross	  FA,	  Hawley	  SA.	  AMPK:	  a	  nutrient	  and	  energy	  sensor	  that	  maintains	  energy	  homeostasis.	  Nature	  Rev	  Mol	  Cell	  Biol	  2012;	  13:	  251-­‐62.	  
D. Grahame Hardie J. Intern. Med. review 21 6	   Hawley	  SA,	  Davison	  M,	  Woods	  A,	  Davies	  SP,	  Beri	  RK,	  Carling	  D,	  Hardie	  DG.	  Characterization	  of	  the	  AMP-­‐activated	  protein	  kinase	  kinase	  from	  rat	  liver,	  and	  identification	  of	  threonine-­‐172	  as	  the	  major	  site	  at	  which	  it	  phosphorylates	  and	  activates	  AMP-­‐activated	  protein	  kinase.	  J	  Biol	  Chem	  1996;	  271:	  27879-­‐87.	  7	   Davies	  SP,	  Sim	  AT,	  Hardie	  DG.	  Location	  and	  function	  of	  three	  sites	  phosphorylated	  on	  rat	  acetyl-­‐CoA	  carboxylase	  by	  the	  AMP-­‐activated	  protein	  kinase.	  Eur	  J	  Biochem	  1990;	  187:	  183-­‐90.	  8	   Gowans	  GJ,	  Hawley	  SA,	  Ross	  FA,	  Hardie	  DG.	  AMP	  is	  a	  true	  physiological	  regulator	  of	  AMP-­‐activated	  protein	  kinase	  by	  both	  allosteric	  activation	  and	  enhancing	  net	  phosphorylation.	  
Cell	  Metab	  2013;	  18:	  556-­‐66.	  9	   Hawley	  SA,	  Boudeau	  J,	  Reid	  JL,	  et	  al.	  Complexes	  between	  the	  LKB1	  tumor	  suppressor,	  STRADα/β	  and	  MO25α/β	  are	  upstream	  kinases	  in	  the	  AMP-­‐activated	  protein	  kinase	  cascade.	  J	  Biol	  2003;	  2:	  28.	  10	   Woods	  A,	  Johnstone	  SR,	  Dickerson	  K,	  et	  al.	  LKB1	  is	  the	  upstream	  kinase	  in	  the	  AMP-­‐activated	  protein	  kinase	  cascade.	  Curr	  Biol	  2003;	  13:	  2004-­‐8.	  11	   Shaw	  RJ,	  Kosmatka	  M,	  Bardeesy	  N,	  Hurley	  RL,	  Witters	  LA,	  DePinho	  RA,	  Cantley	  LC.	  The	  tumor	  suppressor	  LKB1	  kinase	  directly	  activates	  AMP-­‐activated	  kinase	  and	  regulates	  apoptosis	  in	  response	  to	  energy	  stress.	  Proc	  Natl	  Acad	  Sci	  USA	  2004;	  101:	  3329-­‐35.	  12	   Alessi	  DR,	  Sakamoto	  K,	  Bayascas	  JR.	  Lkb1-­‐dependent	  signaling	  pathways.	  Annu	  Rev	  
Biochem	  2006;	  75:	  137-­‐63.	  13	   Xiao	  B,	  Sanders	  MJ,	  Underwood	  E,	  et	  al.	  Structure	  of	  mammalian	  AMPK	  and	  its	  regulation	  by	  ADP.	  Nature	  2011;	  472:	  230-­‐3.	  14	   Hawley	  SA,	  Pan	  DA,	  Mustard	  KJ,	  et	  al.	  Calmodulin-­‐dependent	  protein	  kinase	  kinase-­‐beta	  is	  an	  alternative	  upstream	  kinase	  for	  AMP-­‐activated	  protein	  kinase.	  Cell	  Metab	  2005;	  2:	  9-­‐19.	  15	   Woods	  A,	  Dickerson	  K,	  Heath	  R,	  et	  al.	  Ca2+/calmodulin-­‐dependent	  protein	  kinase	  kinase-­‐beta	  acts	  upstream	  of	  AMP-­‐activated	  protein	  kinase	  in	  mammalian	  cells.	  Cell	  Metab	  2005;	  
2:	  21-­‐33.	  
D. Grahame Hardie J. Intern. Med. review 22 16	   Hurley	  RL,	  Anderson	  KA,	  Franzone	  JM,	  Kemp	  BE,	  Means	  AR,	  Witters	  LA.	  The	  Ca2+/calmoldulin-­‐dependent	  protein	  kinase	  kinases	  are	  AMP-­‐activated	  protein	  kinase	  kinases.	  J	  Biol	  Chem	  2005;	  280:	  29060-­‐6.	  17	   Oakhill	  JS,	  Steel	  R,	  Chen	  ZP,	  Scott	  JW,	  Ling	  N,	  Tam	  S,	  Kemp	  BE.	  AMPK	  is	  a	  direct	  adenylate	  charge-­‐regulated	  protein	  kinase.	  Science	  2011;	  332:	  1433-­‐5.	  18	   Fogarty	  S,	  Hawley	  SA,	  Green	  KA,	  Saner	  N,	  Mustard	  KJ,	  Hardie	  DG.	  Calmodulin-­‐dependent	  protein	  kinase	  kinase-­‐beta	  activates	  AMPK	  without	  forming	  a	  stable	  complex	  -­‐	  synergistic	  effects	  of	  Ca2+	  and	  AMP.	  Biochem	  J	  2010;	  426:	  109-­‐18.	  19	   Tamas	  P,	  Hawley	  SA,	  Clarke	  RG,	  Mustard	  KJ,	  Green	  K,	  Hardie	  DG,	  Cantrell	  DA.	  Regulation	  of	  the	  energy	  sensor	  AMP-­‐activated	  protein	  kinase	  by	  antigen	  receptor	  and	  Ca2+	  in	  T	  lymphocytes.	  J	  Exp	  Med	  2006;	  203:	  1665-­‐70.	  20	   Stahmann	  N,	  Woods	  A,	  Carling	  D,	  Heller	  R.	  Thrombin	  activates	  AMP-­‐activated	  protein	  kinase	  in	  endothelial	  cells	  via	  a	  pathway	  involving	  Ca2+/calmodulin-­‐dependent	  protein	  kinase	  kinase	  beta.	  Mol	  Cell	  Biol	  2006;	  26:	  5933-­‐45.	  21	   Yang	  Y,	  Atasoy	  D,	  Su	  HH,	  Sternson	  SM.	  Hunger	  states	  switch	  a	  flip-­‐flop	  memory	  circuit	  via	  a	  synaptic	  AMPK-­‐dependent	  positive	  feedback	  loop.	  Cell	  2011;	  146:	  992-­‐1003.	  22	   Xiao	  B,	  Sanders	  MJ,	  Carmena	  D,	  et	  al.	  Structural	  basis	  of	  AMPK	  regulation	  by	  small	  molecule	  activators.	  Nature	  Commun	  2013;	  4:	  3017.	  23	   Scott	  JW,	  Norman	  DG,	  Hawley	  SA,	  Kontogiannis	  L,	  Hardie	  DG.	  Protein	  kinase	  substrate	  recognition	  studied	  using	  the	  recombinant	  catalytic	  domain	  of	  AMP-­‐activated	  protein	  kinase	  and	  a	  model	  substrate.	  J	  Mol	  Biol	  2002;	  317:	  309-­‐23.	  24	   Chen	  L,	  Jiao	  ZH,	  Zheng	  LS,	  Zhang	  YY,	  Xie	  ST,	  Wang	  ZX,	  Wu	  JW.	  Structural	  insight	  into	  the	  autoinhibition	  mechanism	  of	  AMP-­‐activated	  protein	  kinase.	  Nature	  2009;	  459:	  1146-­‐9.	  25	   Hudson	  ER,	  Pan	  DA,	  James	  J,	  et	  al.	  A	  novel	  domain	  in	  AMP-­‐activated	  protein	  kinase	  causes	  glycogen	  storage	  bodies	  similar	  to	  those	  seen	  in	  hereditary	  cardiac	  arrhythmias.	  Current	  
Biol	  2003;	  13:	  861-­‐6.	  26	   Polekhina	  G,	  Gupta	  A,	  van	  Denderen	  BJ,	  Feil	  SC,	  Kemp	  BE,	  Stapleton	  D,	  Parker	  MW.	  Structural	  basis	  for	  glycogen	  recognition	  by	  AMP-­‐activated	  protein	  kinase.	  Structure	  
(Camb)	  2005;	  13:	  1453-­‐62.	  
D. Grahame Hardie J. Intern. Med. review 23 27	   Scott	  JW,	  Hawley	  SA,	  Green	  KA,	  et	  al.	  CBS	  domains	  form	  energy-­‐sensing	  modules	  whose	  binding	  of	  adenosine	  ligands	  is	  disrupted	  by	  disease	  mutations.	  J	  Clin	  Invest	  2004;	  113:	  274-­‐84.	  28	   Imamura	  K,	  Ogura	  T,	  Kishimoto	  A,	  Kaminishi	  M,	  Esumi	  H.	  Cell	  cycle	  regulation	  via	  p53	  phosphorylation	  by	  a	  5'-­‐AMP	  activated	  protein	  kinase	  activator,	  5-­‐aminoimidazole-­‐	  4-­‐carboxamide-­‐1-­‐beta-­‐d-­‐	  ribofuranoside,	  in	  a	  human	  hepatocellular	  carcinoma	  cell	  line.	  
Biochem	  Biophys	  Res	  Commun	  2001;	  287:	  562-­‐7.	  29	   He	  G,	  Zhang	  YW,	  Lee	  JH,	  et	  al.	  AMP-­‐activated	  protein	  kinase	  induces	  p53	  by	  phosphorylating	  MDMX	  and	  inhibiting	  its	  activity.	  Mol	  Cell	  Biol	  2014;	  34:	  148-­‐57.	  30	   Chen	  S,	  Wasserman	  DH,	  MacKintosh	  C,	  Sakamoto	  K.	  Mice	  with	  AS160/TBC1D4-­‐Thr649Ala	  knockin	  mutation	  are	  glucose	  intolerant	  with	  reduced	  insulin	  sensitivity	  and	  altered	  GLUT4	  trafficking.	  Cell	  Metab	  2011;	  13:	  68-­‐79.	  31	   Taylor	  EB,	  An	  D,	  Kramer	  HF,	  et	  al.	  Discovery	  of	  TBC1D1	  as	  an	  Insulin-­‐,	  AICAR-­‐,	  and	  Contraction-­‐stimulated	  Signaling	  Nexus	  in	  Mouse	  Skeletal	  Muscle.	  J	  Biol	  Chem	  2008;	  283:	  9787-­‐96.	  32	   Chen	  S,	  Murphy	  J,	  Toth	  R,	  Campbell	  DG,	  Morrice	  NA,	  Mackintosh	  C.	  Complementary	  regulation	  of	  TBC1D1	  and	  AS160	  by	  growth	  factors,	  insulin	  and	  AMPK	  activators.	  Biochem	  
J	  2008;	  409:	  449-­‐59.	  33	   Pehmoller	  C,	  Treebak	  JT,	  Birk	  JB,	  et	  al.	  Genetic	  disruption	  of	  AMPK	  signaling	  abolishes	  both	  contraction-­‐	  and	  insulin-­‐stimulated	  TBC1D1	  phosphorylation	  and	  14-­‐3-­‐3	  binding	  in	  mouse	  skeletal	  muscle.	  Am	  J	  Physiol	  Endocrinol	  Metab	  2009;	  297:	  E665-­‐E75.	  34	   Hatakeyama	  H,	  Kanzaki	  M.	  Regulatory	  mode	  shift	  of	  Tbc1d1	  is	  required	  for	  acquisition	  of	  insulin-­‐responsive	  GLUT4-­‐trafficking	  activity.	  Mol	  Biol	  Cell	  2013;	  24:	  809-­‐17.	  35	   Corton	  JM,	  Gillespie	  JG,	  Hawley	  SA,	  Hardie	  DG.	  5-­‐Aminoimidazole-­‐4-­‐carboxamide	  ribonucleoside:	  a	  specific	  method	  for	  activating	  AMP-­‐activated	  protein	  kinase	  in	  intact	  cells?	  Eur	  J	  Biochem	  1995;	  229:	  558-­‐65.	  36	   Merrill	  GM,	  Kurth	  E,	  Hardie	  DG,	  Winder	  WW.	  AICAR	  decreases	  malonyl-­‐CoA	  and	  increases	  fatty	  acid	  oxidation	  in	  skeletal	  muscle	  of	  the	  rat.	  Am	  J	  Physiol	  1997;	  273:	  E1107-­‐E12.	  
D. Grahame Hardie J. Intern. Med. review 24 37	   Jager	  S,	  Handschin	  C,	  St-­‐Pierre	  J,	  Spiegelman	  BM.	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  action	  in	  skeletal	  muscle	  via	  direct	  phosphorylation	  of	  PGC-­‐1{alpha}.	  Proc	  Natl	  Acad	  Sci	  
USA	  2007;	  104:	  12017-­‐22.	  38	   Canto	  C,	  Jiang	  LQ,	  Deshmukh	  AS,	  et	  al.	  Interdependence	  of	  AMPK	  and	  SIRT1	  for	  metabolic	  adaptation	  to	  fasting	  and	  exercise	  in	  skeletal	  muscle.	  Cell	  Metab	  2010;	  11:	  213-­‐9.	  39	   Li	  Y,	  Xu	  S,	  Mihaylova	  MM,	  et	  al.	  AMPK	  phosphorylates	  and	  Inhibits	  SREBP	  activity	  to	  attenuate	  hepatic	  steatosis	  and	  atherosclerosis	  in	  diet-­‐induced	  insulin-­‐resistant	  mice.	  Cell	  
Metab	  2011;	  13:	  376-­‐88.	  40	   Muoio	  DM,	  Seefeld	  K,	  Witters	  LA,	  Coleman	  RA.	  AMP-­‐activated	  kinase	  reciprocally	  regulates	  triacylglycerol	  synthesis	  and	  fatty	  acid	  oxidation	  in	  liver	  and	  muscle:	  evidence	  that	  sn-­‐glycerol-­‐	  3-­‐phosphate	  acyltransferase	  is	  a	  novel	  target.	  Biochem	  J	  1999;	  338:	  783-­‐91.	  41	   Inoki	  K,	  Zhu	  T,	  Guan	  KL.	  TSC2	  mediates	  cellular	  energy	  response	  to	  control	  cell	  growth	  and	  survival.	  Cell	  2003;	  115:	  577-­‐90.	  42	   Gwinn	  DM,	  Shackelford	  DB,	  Egan	  DF,	  et	  al.	  AMPK	  phosphorylation	  of	  raptor	  mediates	  a	  metabolic	  checkpoint.	  Mol	  Cell	  2008;	  30:	  214-­‐26.	  43	   Hoppe	  S,	  Bierhoff	  H,	  Cado	  I,	  Weber	  A,	  Tiebe	  M,	  Grummt	  I,	  Voit	  R.	  AMP-­‐activated	  protein	  kinase	  adapts	  rRNA	  synthesis	  to	  cellular	  energy	  supply.	  Proc	  Natl	  Acad	  Sci	  USA	  2009;	  106:	  17781-­‐6.	  44	   Arad	  M,	  Seidman	  CE,	  Seidman	  JG.	  AMP-­‐activated	  protein	  kinase	  in	  the	  heart:	  role	  during	  health	  and	  disease.	  Circ	  Res	  2007;	  100:	  474-­‐88.	  45	   Gollob	  MH,	  Seger	  JJ,	  Gollob	  TN,	  Tapscott	  T,	  Gonzales	  O,	  Bachinski	  L,	  Roberts	  R.	  Novel	  PRKAG2	  mutation	  responsible	  for	  the	  genetic	  syndrome	  of	  ventricular	  preexcitation	  and	  conduction	  system	  disease	  with	  childhood	  onset	  and	  absence	  of	  cardiac	  hypertrophy.	  
Circulation	  2001;	  104:	  3030-­‐3.	  46	   Akman	  HO,	  Sampayo	  JN,	  Ross	  FA,	  et	  al.	  Fatal	  infantile	  cardiac	  glycogenosis	  with	  phosphorylase	  kinase	  deficiency	  and	  a	  mutation	  in	  the	  gamma-­‐2	  subunit	  of	  AMP-­‐activated	  protein	  kinase.	  Pediatr	  Res	  2007;	  62:	  499-­‐504.	  
D. Grahame Hardie J. Intern. Med. review 25 47	   Burwinkel	  B,	  Scott	  JW,	  Buhrer	  C,	  et	  al.	  Fatal	  congenital	  heart	  glycogenosis	  caused	  by	  a	  recurrent	  activating	  R531Q	  mutation	  in	  the	  g2	  subunit	  of	  AMP-­‐activated	  protein	  kinase	  (PRKAG2),	  not	  by	  phosphorylase	  kinase	  deficiency.	  Am	  J	  Hum	  Genet	  2005;	  76:	  1034-­‐49.	  48	   Xiao	  B,	  Heath	  R,	  Saiu	  P,	  et	  al.	  Structural	  basis	  for	  AMP	  binding	  to	  mammalian	  AMP-­‐activated	  protein	  kinase.	  Nature	  2007;	  449:	  496-­‐500.	  49	   Daniel	  TD,	  Carling	  D.	  Functional	  analysis	  of	  mutations	  in	  the	  γ2	  subunit	  of	  AMP-­‐activated	  protein	  kinase	  associated	  with	  cardiac	  hypertrophy	  and	  Wolff-­‐Parkinson-­‐White	  syndrome.	  J	  Biol	  Chem	  2002;	  277:	  51017-­‐24.	  50	   Hawley	  SA,	  Ross	  FA,	  Chevtzoff	  C,	  et	  al.	  Use	  of	  cells	  expressing	  gamma	  subunit	  variants	  to	  identify	  diverse	  mechanisms	  of	  AMPK	  activation.	  Cell	  Metab	  2010;	  11:	  554-­‐65.	  51	   Arad	  M,	  D.W.	  B,	  Perez-­‐Atayde	  AR,	  et	  al.	  Constitutively	  active	  AMP	  kinase	  mutations	  cause	  glycogen	  storage	  disease	  mimicking	  hypertrophic	  cardiomyopathy.	  J	  Clin	  Invest	  2002;	  
109:	  357-­‐62.	  52	   Arad	  M,	  Moskowitz	  IP,	  Patel	  VV,	  et	  al.	  Transgenic	  mice	  overexpressing	  mutant	  PRKAG2	  define	  the	  cause	  of	  Wolff-­‐Parkinson-­‐White	  syndrome	  in	  glycogen	  storage	  cardiomyopathy.	  Circulation	  2003;	  107:	  2850-­‐6.	  53	   Sidhu	  JS,	  Rajawat	  YS,	  Rami	  TG,	  et	  al.	  Transgenic	  Mouse	  Model	  of	  Ventricular	  Preexcitation	  and	  Atrioventricular	  Reentrant	  Tachycardia	  Induced	  by	  an	  AMP-­‐Activated	  Protein	  Kinase	  Loss-­‐of-­‐Function	  Mutation	  Responsible	  for	  Wolff-­‐Parkinson-­‐White	  Syndrome.	  Circulation	  2004.	  54	   Davies	  JK,	  Wells	  DJ,	  Liu	  K,	  et	  al.	  Characterization	  of	  the	  role	  of	  gamma2	  R531G	  mutation	  in	  AMP-­‐activated	  protein	  kinase	  in	  cardiac	  hypertrophy	  and	  Wolff-­‐Parkinson-­‐White	  syndrome.	  Am	  J	  Physiol	  Heart	  Circ	  Physiol	  2006;	  290:	  H1942-­‐H51.	  55	   Luptak	  I,	  Shen	  M,	  He	  H,	  et	  al.	  Aberrant	  activation	  of	  AMP-­‐activated	  protein	  kinase	  remodels	  metabolic	  network	  in	  favor	  of	  cardiac	  glycogen	  storage.	  J	  Clin	  Invest	  2007;	  117:	  1432-­‐9.	  56	   Kim	  M,	  Hunter	  RW,	  Garcia-­‐Menendez	  L,	  et	  al.	  Mutation	  in	  the	  gamma-2	  subunit	  of	  AMPK	  stimulates	  cardiomyocyte	  proliferation	  and	  hypertrophy	  independent	  of	  glycogen	  storage.	  Circ	  Res	  2014:	  in	  press.	  
D. Grahame Hardie J. Intern. Med. review 26 57	   Cheung	  PCF,	  Salt	  IP,	  Davies	  SP,	  Hardie	  DG,	  Carling	  D.	  Characterization	  of	  AMP-­‐activated	  protein	  kinase	  γ	  subunit	  isoforms	  and	  their	  role	  in	  AMP	  binding.	  Biochem	  J	  2000;	  346:	  659-­‐69.	  58	   Milan	  D,	  Jeon	  JT,	  Looft	  C,	  et	  al.	  A	  mutation	  in	  PRKAG3	  associated	  with	  excess	  glycogen	  content	  in	  pig	  skeletal	  muscle.	  Science	  2000;	  288:	  1248-­‐51.	  59	   Holmes	  BF,	  Kurth-­‐Kraczek	  EJ,	  Winder	  WW.	  Chronic	  activation	  of	  5'-­‐AMP-­‐activated	  protein	  kinase	  increases	  GLUT-­‐4,	  hexokinase,	  and	  glycogen	  in	  muscle.	  J	  Appl	  Physiol	  1999;	  87:	  1990-­‐5.	  60	   Narkar	  VA,	  Downes	  M,	  Yu	  RT,	  et	  al.	  AMPK	  and	  PPARdelta	  agonists	  are	  exercise	  mimetics.	  
Cell	  2008;	  134:	  405-­‐15.	  61	   Samuel	  VT,	  Petersen	  KF,	  Shulman	  GI.	  Lipid-­‐induced	  insulin	  resistance:	  unravelling	  the	  mechanism.	  Lancet	  2010;	  375:	  2267-­‐77.	  62	   Shoelson	  SE,	  Lee	  J,	  Goldfine	  AB.	  Inflammation	  and	  insulin	  resistance.	  J	  Clin	  Invest	  2006;	  
116:	  1793-­‐801.	  63	   Fu	  S,	  Watkins	  SM,	  Hotamisligil	  GS.	  The	  role	  of	  endoplasmic	  reticulum	  in	  hepatic	  lipid	  homeostasis	  and	  stress	  signaling.	  Cell	  Metab	  2012;	  15:	  623-­‐34.	  64	   O'Neill	  HM,	  Maarbjerg	  SJ,	  Crane	  JD,	  et	  al.	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  {beta}1{beta}2	  muscle	  null	  mice	  reveal	  an	  essential	  role	  for	  AMPK	  in	  maintaining	  mitochondrial	  content	  and	  glucose	  uptake	  during	  exercise.	  Proc	  Natl	  Acad	  Sci	  USA	  2011;	  
108:	  16092-­‐7.	  65	   Lochhead	  PA,	  Salt	  IP,	  Walker	  KS,	  Hardie	  DG,	  Sutherland	  C.	  5-­‐aminoimidazole-­‐4-­‐carboxamide	  riboside	  mimics	  the	  effects	  of	  insulin	  on	  the	  expression	  of	  the	  2	  key	  gluconeogenic	  genes	  PEPCK	  and	  glucose-­‐6-­‐phosphatase.	  Diabetes	  2000;	  49:	  896-­‐903.	  66	   Koo	  SH,	  Flechner	  L,	  Qi	  L,	  et	  al.	  The	  CREB	  coactivator	  TORC2	  is	  a	  key	  regulator	  of	  fasting	  glucose	  metabolism.	  Nature	  2005;	  437:	  1109-­‐14.	  67	   Bergeron	  R,	  Previs	  SF,	  Cline	  GW,	  Perret	  P,	  Russell	  RR,	  3rd,	  Young	  LH,	  Shulman	  GI.	  Effect	  of	  5-­‐aminoimidazole-­‐4-­‐carboxamide-­‐1-­‐beta-­‐D-­‐ribofuranoside	  infusion	  on	  in	  vivo	  glucose	  and	  lipid	  metabolism	  in	  lean	  and	  obese	  Zucker	  rats.	  Diabetes	  2001;	  50:	  1076-­‐82.	  
D. Grahame Hardie J. Intern. Med. review 27 68	   Buhl	  ES,	  Jessen	  N,	  Pold	  R,	  et	  al.	  Long-­‐term	  AICAR	  administration	  reduces	  metabolic	  disturbances	  and	  lowers	  blood	  pressure	  in	  rats	  displaying	  features	  of	  the	  insulin	  resistance	  syndrome.	  Diabetes	  2002;	  51:	  2199-­‐206.	  69	   Song	  XM,	  Fiedler	  M,	  Galuska	  D,	  et	  al.	  5-­‐Aminoimidazole-­‐4-­‐caboxamide	  ribonucleoside	  treatment	  improves	  glucose	  homeostasis	  in	  insulin-­‐resistant	  diabetic	  (ob/ob)	  mice.	  
Diabetologia	  2002;	  45:	  56-­‐65.	  70	   Iglesias	  MA,	  Ye	  JM,	  Frangioudakis	  G,	  et	  al.	  AICAR	  administration	  causes	  an	  apparent	  enhancement	  of	  muscle	  and	  liver	  insulin	  action	  in	  insulin-­‐resistant	  high-­‐fat-­‐fed	  rats.	  
Diabetes	  2002;	  51:	  2886-­‐94.	  71	   Zhou	  G,	  Myers	  R,	  Li	  Y,	  et	  al.	  Role	  of	  AMP-­‐activated	  protein	  kinase	  in	  mechanism	  of	  metformin	  action.	  J	  Clin	  Invest	  2001;	  108:	  1167-­‐74.	  72	   Cool	  B,	  Zinker	  B,	  Chiou	  W,	  et	  al.	  Identification	  and	  characterization	  of	  a	  small	  molecule	  AMPK	  activator	  that	  treats	  key	  components	  of	  type	  2	  diabetes	  and	  the	  metabolic	  syndrome.	  Cell	  Metab	  2006;	  3:	  403-­‐16.	  73	   Lee	  YS,	  Kim	  WS,	  Kim	  KH,	  et	  al.	  Berberine,	  a	  natural	  plant	  product,	  activates	  AMP-­‐activated	  protein	  kinase	  with	  beneficial	  metabolic	  effects	  in	  diabetic	  and	  insulin-­‐resistant	  states.	  
Diabetes	  2006;	  55:	  2256-­‐64.	  74	   Foretz	  M,	  Hebrard	  S,	  Leclerc	  J,	  et	  al.	  Metformin	  inhibits	  hepatic	  gluconeogenesis	  in	  mice	  independently	  of	  the	  LKB1/AMPK	  pathway	  via	  a	  decrease	  in	  hepatic	  energy	  state.	  J	  Clin	  
Invest	  2010;	  120:	  2355-­‐69.	  75	   Vincent	  MF,	  Marangos	  PJ,	  Gruber	  HE,	  Van	  den	  Berghe	  G.	  Inhibition	  by	  AICA	  riboside	  of	  gluconeogenesis	  in	  isolated	  rat	  hepatocytes.	  Diabetes	  1991;	  40:	  1259-­‐66.	  76	   Miller	  RA,	  Chu	  Q,	  Xie	  J,	  Foretz	  M,	  Viollet	  B,	  Birnbaum	  MJ.	  Biguanides	  suppress	  hepatic	  glucagon	  signalling	  by	  decreasing	  production	  of	  cyclic	  AMP.	  Nature	  2013;	  494:	  256-­‐60.	  77	   Fullerton	  MD,	  Galic	  S,	  Marcinko	  K,	  et	  al.	  Single	  phosphorylation	  sites	  in	  ACC1	  and	  ACC2	  regulate	  lipid	  homeostasis	  and	  the	  insulin-­‐sensitizing	  effects	  of	  metformin.	  Nat	  Med	  2013;	  
19:	  1649-­‐54.	  78	   Miyoshi	  H,	  Nakau	  M,	  Ishikawa	  TO,	  Seldin	  MF,	  Oshima	  M,	  Taketo	  MM.	  Gastrointestinal	  hamartomatous	  polyposis	  in	  LKB1	  heterozygous	  knockout	  mice.	  Cancer	  Res	  2002;	  62:	  2261-­‐6.	  
D. Grahame Hardie J. Intern. Med. review 28 79	   Nakau	  M,	  Miyoshi	  H,	  Seldin	  MF,	  Imamura	  M,	  Oshima	  M,	  Taketo	  MM.	  Hepatocellular	  carcinoma	  caused	  by	  loss	  of	  heterozygosity	  in	  LKB1	  gene	  knockout	  mice.	  Cancer	  Res	  2002;	  62:	  4549-­‐53.	  80	   Lizcano	  JM,	  Göransson	  O,	  Toth	  R,	  et	  al.	  LKB1	  is	  a	  master	  kinase	  that	  activates	  13	  protein	  kinases	  of	  the	  AMPK	  subfamily,	  including	  the	  MARK/PAR-­‐1	  kinases.	  EMBO	  J	  2004;	  23:	  833-­‐43.	  81	   Vander	  Heiden	  MG,	  Cantley	  LC,	  Thompson	  CB.	  Understanding	  the	  Warburg	  effect:	  the	  metabolic	  requirements	  of	  cell	  proliferation.	  Science	  2009;	  324:	  1029-­‐33.	  82	   Huang	  X,	  Wullschleger	  S,	  Shpiro	  N,	  et	  al.	  Important	  role	  of	  the	  LKB1-­‐AMPK	  pathway	  in	  suppressing	  tumorigenesis	  in	  PTEN-­‐deficient	  mice.	  Biochem	  J	  2008;	  412:	  211-­‐21.	  83	   Faubert	  B,	  Boily	  G,	  Izreig	  S,	  et	  al.	  AMPK	  Is	  a	  negative	  regulator	  of	  the	  Warburg	  effect	  and	  suppresses	  tumor	  growth	  In	  vivo.	  Cell	  Metab	  2012;	  17:	  113-­‐24.	  84	   Thomas	  GV,	  Tran	  C,	  Mellinghoff	  IK,	  et	  al.	  Hypoxia-­‐inducible	  factor	  determines	  sensitivity	  to	  inhibitors	  of	  mTOR	  in	  kidney	  cancer.	  Nat	  Med	  2006;	  12:	  122-­‐7.	  85	   Evans	  JM,	  Donnelly	  LA,	  Emslie-­‐Smith	  AM,	  Alessi	  DR,	  Morris	  AD.	  Metformin	  and	  reduced	  risk	  of	  cancer	  in	  diabetic	  patients.	  BMJ	  2005;	  330:	  1304-­‐5.	  86	   Noto	  H,	  Goto	  A,	  Tsujimoto	  T,	  Noda	  M.	  Cancer	  risk	  in	  diabetic	  patients	  treated	  with	  metformin:	  a	  systematic	  review	  and	  meta-­‐analysis.	  PloS	  one	  2012;	  7:	  e33411.	  87	   Algire	  C,	  Amrein	  L,	  Bazile	  M,	  David	  S,	  Zakikhani	  M,	  Pollak	  M.	  Diet	  and	  tumor	  LKB1	  expression	  interact	  to	  determine	  sensitivity	  to	  anti-­‐neoplastic	  effects	  of	  metformin	  in	  vivo.	  Oncogene	  2011;	  30:	  1174-­‐82.	  88	   Shackelford	  DB,	  Abt	  E,	  Gerken	  L,	  et	  al.	  LKB1	  inactivation	  dictates	  therapeutic	  response	  of	  non-­‐small	  cell	  lung	  cancer	  to	  the	  metabolism	  drug	  phenformin.	  Cancer	  Cell	  2013;	  23:	  143-­‐58.	  89	   Sanchez-­‐Cespedes	  M,	  Parrella	  P,	  Esteller	  M,	  et	  al.	  Inactivation	  of	  LKB1/STK11	  is	  a	  common	  event	  in	  adenocarcinomas	  of	  the	  lung.	  Cancer	  Res	  2002;	  62:	  3659-­‐62.	  90	   Ji	  H,	  Ramsey	  MR,	  Hayes	  DN,	  et	  al.	  LKB1	  modulates	  lung	  cancer	  differentiation	  and	  metastasis.	  Nature	  2007;	  448:	  807-­‐10.	  91	   Wingo	  SN,	  Gallardo	  TD,	  Akbay	  EA,	  et	  al.	  Somatic	  LKB1	  mutations	  promote	  cervical	  cancer	  progression.	  PLoS	  ONE	  2009;	  4:	  e5137.	  
D. Grahame Hardie J. Intern. Med. review 29 92	   Liu	  W,	  Monahan	  KB,	  Pfefferle	  AD,	  et	  al.	  LKB1/STK11	  inactivation	  leads	  to	  expansion	  of	  a	  prometastatic	  tumor	  subpopulation	  in	  melanoma.	  Cancer	  Cell	  2012;	  21:	  751-­‐64.	  93	   Lee	  CW,	  Wong	  LL,	  Tse	  EY,	  et	  al.	  AMPK	  promotes	  p53	  acetylation	  via	  phosphorylation	  and	  inactivation	  of	  SIRT1	  in	  liver	  cancer	  cells.	  Cancer	  Res	  2012;	  72:	  4394-­‐404.	  94	   Yuan	  TL,	  Cantley	  LC.	  PI3K	  pathway	  alterations	  in	  cancer:	  variations	  on	  a	  theme.	  Oncogene	  2008;	  27:	  5497-­‐510.	  95	   Horman	  S,	  Vertommen	  D,	  Heath	  R,	  et	  al.	  Insulin	  antagonizes	  ischemia-­‐induced	  Thr172	  phosphorylation	  of	  AMP-­‐activated	  protein	  kinase	  alpha-­‐subunits	  in	  heart	  via	  hierarchical	  phosphorylation	  of	  Ser485/491.	  J	  Biol	  Chem	  2006;	  281:	  5335-­‐40.	  96	   Hawley	  SA,	  Ross	  FA,	  Gowans	  GJ,	  Tibarewal	  P,	  Leslie	  NR,	  Hardie	  DG.	  Phosphorylation	  by	  Akt	  within	  the	  ST	  loop	  of	  AMPK-­‐α1	  down-­‐regulates	  its	  activation	  in	  tumour	  cells.	  Biochem	  
J	  2014:	  in	  press	  (DOI:	  10.1042/BJ20131344).	  97	   Steinberg	  GR,	  Dandapani	  M,	  Hardie	  DG.	  AMPK:	  mediating	  the	  metabolic	  effects	  of	  salicylate-­‐based	  drugs?	  Trends	  Endocrinol	  Metab	  2013;	  24:	  481-­‐7.	  98	   Krawczyk	  CM,	  Holowka	  T,	  Sun	  J,	  et	  al.	  Toll-­‐like	  receptor-­‐induced	  changes	  in	  glycolytic	  metabolism	  regulate	  dendritic	  cell	  activation.	  Blood	  2010;	  115:	  4742-­‐9.	  99	   Sag	  D,	  Carling	  D,	  Stout	  RD,	  Suttles	  J.	  Adenosine	  5'-­‐monophosphate-­‐activated	  protein	  kinase	  promotes	  macrophage	  polarization	  to	  an	  anti-­‐inflammatory	  functional	  phenotype.	  
J	  Immunol	  2008;	  181:	  8633-­‐41.	  100	  Yang	  Z,	  Kahn	  BB,	  Shi	  H,	  Xue	  BZ.	  Macrophage	  {alpha}1-­‐AMP-­‐activated	  protein	  kinase	  ({alpha}1AMPK)	  antagonizes	  fatty	  acid-­‐induced	  inflammation	  through	  SIRT1.	  J	  Biol	  Chem	  2010;	  285:	  19051-­‐9.	  101	  Galic	  S,	  Fullerton	  MD,	  Schertzer	  JD,	  et	  al.	  Hematopoietic	  AMPK	  beta1	  reduces	  mouse	  adipose	  tissue	  macrophage	  inflammation	  and	  insulin	  resistance	  in	  obesity.	  J	  Clin	  Invest	  2011;	  121:	  4903-­‐15.	  102	  Mounier	  R,	  Theret	  M,	  Arnold	  L,	  et	  al.	  AMPKalpha1	  regulates	  macrophage	  skewing	  at	  the	  time	  of	  resolution	  of	  inflammation	  during	  skeletal	  muscle	  regeneration.	  Cell	  Metab	  2013;	  
18:	  251-­‐64.	  103	  Hawley	  SA,	  Fullerton	  MD,	  Ross	  FA,	  et	  al.	  The	  ancient	  drug	  salicylate	  directly	  activates	  AMP-­‐activated	  protein	  kinase.	  Science	  2012;	  336:	  918-­‐22.	  
D. Grahame Hardie J. Intern. Med. review 30 104	  Amann	  R,	  Peskar	  BA.	  Anti-­‐inflammatory	  effects	  of	  aspirin	  and	  sodium	  salicylate.	  Eur	  J	  
Pharmacol	  2002;	  447:	  1-­‐9.	  105	  April	  P,	  Abeles	  M,	  Baraf	  H,	  et	  al.	  Does	  the	  acetyl	  group	  of	  aspirin	  contribute	  to	  the	  antiinflammatory	  efficacy	  of	  salicylic	  acid	  in	  the	  treatment	  of	  rheumatoid	  arthritis?	  Sem	  
Arth	  Rheum	  1990;	  19:	  20-­‐8.	  106	  Rothwell	  PM,	  Fowkes	  FG,	  Belch	  JF,	  Ogawa	  H,	  Warlow	  CP,	  Meade	  TW.	  Effect	  of	  daily	  aspirin	  on	  long-­‐term	  risk	  of	  death	  due	  to	  cancer:	  analysis	  of	  individual	  patient	  data	  from	  randomised	  trials.	  Lancet	  2011;	  377:	  31-­‐41.	  107	  Mankouri	  J,	  Tedbury	  PR,	  Gretton	  S,	  et	  al.	  Enhanced	  hepatitis	  C	  virus	  genome	  replication	  and	  lipid	  accumulation	  mediated	  by	  inhibition	  of	  AMP-­‐activated	  protein	  kinase.	  Proc	  Natl	  
Acad	  Sci	  USA	  2010;	  107:	  11549-­‐54.	  108	  Street	  A,	  Macdonald	  A,	  Crowder	  K,	  Harris	  M.	  The	  Hepatitis	  C	  virus	  NS5A	  protein	  activates	  a	  phosphoinositide	  3-­‐kinase-­‐dependent	  survival	  signaling	  cascade.	  J	  Biol	  Chem	  2004;	  279:	  12232-­‐41.	  109	  Mankouri	  J,	  Harris	  M.	  Viruses	  and	  the	  fuel	  sensor:	  the	  emerging	  link	  between	  AMPK	  and	  virus	  replication.	  Reviews	  Med	  Virol	  2011;	  21:	  205-­‐12.	  110	  Wang	  DS,	  Jonker	  JW,	  Kato	  Y,	  Kusuhara	  H,	  Schinkel	  AH,	  Sugiyama	  Y.	  Involvement	  of	  organic	  cation	  transporter	  1	  in	  hepatic	  and	  intestinal	  distribution	  of	  metformin.	  J	  
Pharmacol	  Exp	  Ther	  2002;	  302:	  510-­‐5.	  111	  Bailey	  CJ,	  Wilcock	  C,	  Day	  C.	  Effect	  of	  metformin	  on	  glucose	  metabolism	  in	  the	  splanchnic	  bed.	  Br	  J	  Pharmacol	  1992;	  105:	  1009-­‐13.	  112	  Wang	  DS,	  Kusuhara	  H,	  Kato	  Y,	  Jonker	  JW,	  Schinkel	  AH,	  Sugiyama	  Y.	  Involvement	  of	  organic	  cation	  transporter	  1	  in	  the	  lactic	  acidosis	  caused	  by	  metformin.	  Mol	  Pharmacol	  2003;	  63:	  844-­‐8.	  113	  Cuthbertson	  DJ,	  Babraj	  JA,	  Mustard	  KJ,	  et	  al.	  5-­‐aminoimidazole-­‐4-­‐carboxamide	  1-­‐beta-­‐D-­‐ribofuranoside	  acutely	  stimulates	  skeletal	  muscle	  2-­‐deoxyglucose	  uptake	  in	  healthy	  men.	  
Diabetes	  2007;	  56:	  2078-­‐84.	  114	  Wolf	  CM,	  Arad	  M,	  Ahmad	  F,	  et	  al.	  Reversibility	  of	  PRKAG2	  glycogen-­‐storage	  cardiomyopathy	  and	  electrophysiological	  manifestations.	  Circulation	  2008;	  117:	  144-­‐54.	  
D. Grahame Hardie J. Intern. Med. review 31 115	  Yu	  PB,	  Hong	  CC,	  Sachidanandan	  C,	  et	  al.	  Dorsomorphin	  inhibits	  BMP	  signals	  required	  for	  embryogenesis	  and	  iron	  metabolism.	  Nat	  Chem	  Biol	  2008;	  4:	  33-­‐41.	  116	  Bain	  J,	  Plater	  L,	  Elliott	  M,	  et	  al.	  The	  selectivity	  of	  protein	  kinase	  inhibitors:	  a	  further	  update.	  Biochem	  J	  2007;	  408:	  297-­‐315.	  117	  Abu-­‐Elheiga	  L,	  Matzuk	  MM,	  Abo-­‐Hashema	  KA,	  Wakil	  SJ.	  Continuous	  fatty	  acid	  oxidation	  and	  reduced	  fat	  storage	  in	  mice	  lacking	  acetyl-­‐CoA	  carboxylase	  2.	  Science	  2001;	  291:	  2613-­‐6.	  	  
 
D. Grahame Hardie J. Intern. Med. review 32 
FIGURE LEGENDS: 
Figure 1: Structure of the heterotrimeric AMPK complex. The linear layout of the domains is 
shown at the top, and a three dimensional model of a human α2β1γ1  complex (created 
in MacPyMol from the RCSB ProteinDataBank entry 4CFE [22]) at the bottom, using 
similar color coding. From the view at the bottom, the complex can be seen to be 
divided into two rather separate regions, the “catalytic module” at top left, and the 
“nucleotide-binding module” at bottom right, with Thr172 partially exposed in the 
narrow cleft between them. The activators AMP (only shown in sites 1 and 3) and 991, 
the inhibitor staurosporine, and the side chain of Thr172 are in “sphere” view with C 
atoms in green, O in red, and N in blue (H omitted). The extended linker that connects 
the α-AID and the α-CTD, which wraps around one face of the γ subunit, is in “stick” 
view in deep blue color. All other domains are in “cartoon” view with α-helices 
represented as cylinders and β-strands as ribbons. The “ST loop” a regulatory region 
referred to in the text, was not resolved in this structure, but its approximate location is 
shown by a black dashed line. 
Figure 2: Summary of selected protein targets and processes downstream of AMPK. A green 
arrow signifies activation, and a red line with a cross-bar signifies inhibition. Note that 
if AMPK inhibits a protein that in turn inhibits a downstream process, (two successive 
red lines with cross-bars) then the overall process (e.g. glucose uptake, fatty acid 
oxidation) will be activated. A question mark next to a protein signifies that it is not 
certain that the protein is a direct target for AMPK. 
Figure 3: Model for acute activation of glucose transport in muscle by AMPK. In the 
unphosphorylated form, the protein TBC1D1 retains GLUT4 at intracellular sites 
because its Rab-GAP domain promotes the inactive GDP-bound state of members of the 
Rab family of small G proteins. AMPK phosphorylates TBC1D1 at Ser237 near the 
PTB1 domain, while Akt (and perhaps also AMPK?) phosphorylates Thr596 near 
PTB2. This dual phosphorylation promotes the binding of 14:3:3 proteins, abundant 
dimeric proteins containing two symmetrical pockets that bind to phosphorylated 
peptides, which is proposed to inhibit the Rab-GAP activity of TBC1D1. The functions 
of the two phosphotyrosine-binding (PTB) domains of TBC1D1 remain unclear. 
D. Grahame Hardie J. Intern. Med. review 33 
Figure 4: Acute activation of fatty acid oxidation and inhibition of fatty acid synthesis by 
AMPK. AMPK phosphorylates both isoforms ACC1 and ACC2 at equivalent sites 
(Ser80 and Ser221 in human ACC1 and ACC2 respectively), causing their inactivation. 
This lowers malonyl-CoA, a key intermediate in fatty acid synthesis that is also an 
inhibitor of carnitine palmitoyl transferase-1 (CPT1). CPT1 is involved in uptake of 
fatty acids into mitochondria, where they are oxidized to generate ATP. It was thought 
that ACC1 produced the pool of malonyl-CoA involved in fatty acid synthesis, and 
ACC2 a separate pool of malonyl-CoA that regulates CPT1 [117], but recent results 
suggest that these two pools cannot be completely distinct [77]. 
Figure 5: Growth factors activate, whereas energy stress and AMPK inactivate, the 
mechanistic target-of-rapamycin complex 1 (mTORC1). mTORC1 is a large 
multiprotein complex containing mTOR and Raptor, which phosphorylates and 
activates S6 kinase-1, an activator of protein synthesis, and phosphorylates and 
inactivates initiation factor 4E-binding protein-1 (4E-BP1), an inhibitor of protein 
synthesis. Binding of the active GTP-bound form of the small G protein Rheb recruits 
mTORC1 to the lysosome, where it is activated. Growth factors activate the protein 
kinase B/Akt pathway and the Erk pathway, and both of those protein kinases 
phosphorylate the TSC2 component of the TSC1:TSC2 complex, inhibiting its Rheb-
GAP activity and thus activating mTORC1. PKB/Akt also phosphorylates PRAS40, 
relieving its inhibitory effect on mTORC1. On the other hand AMPK, activated in 
response to energy stress, phosphorylates TSC2, enhancing its Rheb-GAP activity, as 
well as Raptor, with both effects inhibiting mTORC1. 
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